產(chǎn)品概述

Description：The clustered regularly interspaced short palindromic repeats, known as CRISPR systems are adaptive immune mechanisms commonly present in archaea and bacteria. The CRISPR systems enable the host to specifically target and cleave foreign nucleic acids thus targeting infectiousviruses and plasmids. Recently, a type V CRISPR system has been identified in several bacteria, the Cpf1 CRISPR from Prevotella and Francisella 1. In contrast to Cas9 systems, CRISPR/Cpf1 systems are smaller in size, do not require an additional trans-activating crRNA (tracrRNA), and allow for targeting of additional genomic regions by cleaveing the target DNA proceeded by a short T-rich protospacer-adjacent motif (PAM). On the other hand, the Cas9 system requires a G-rich PAM following the target DNA. Furthermore, Cas12a/Cpf1 introduces a staggered DNA double stranded break with a 4 or 5-nt 5’ overhang. Recombinant Acidaminococcus sp. BV3L6 Cas12a (cpf1) nuclease is expressed in E. coli and purified. The nuclease contains nuclear localization sequence (NLS) at the C-terminus and 6× His-tag at the C-terminus.

Key Features：High knockout efficiencies: Consistent high performance in in-vitro plasmid cleavage test.

                       Time-saving: no need for transcription and translation. 

                       DNA-free: no external DNA added to system.

應用指導

crRNA -dependent double-stranded DNA cleavage.

產(chǎn)品屬性

Source：Recombinant Cas12a with an C-terminal NLS expressed by E.coli.

Species：Acidaminococcus sp. (strain BV3L6)

Tag：C-terminal 6× His Tag

Apparent Molecular Weight：~150 kDa, on SDS-PAGE under reducing conditions.

Concentration：4(±10%) mg/ml

Active temperature：This Cas12a is active at 37℃.

Storage Buffer：20 mM Sodium Acetate, 500 mM NaCl, 1 mM TCEP，0.1 mM EDTA, 50% glycerol, PH6.0.

Storage & Stability：This product remains stable up to 18 months at -20℃. Avoid repeated freeze-thaw cycles.

Accession#：U2UMQ6

質(zhì)控參數(shù)

Appearance：Clear, colorless liquid

Purity：≥ 90% by SDS-PAGE

Concentration：4(±10%) mg/m

Bioactivity：≥ 90%

Residual DNase：Undetectable

Residual RNase：Undetectable

Endotoxin Level：≤ 0.1 EU/μg of the protein by gel clotting method

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.